%0 Journal Article
%A Safi, S.
%A Krzykalla, J.
%A Hoffmann, H.
%A Benner, A.
%A Bischoff, H.
%A Eichhorn, M.
%A Kriegsmann, M.
%A Poschke, I.
%A Stögbauer, F.
%A Umansky, Ludmila
%A Mogler, C.
%A Weichert, W.
%A Winter, H.
%A Beckhove, P.
%A Muley, T.
%T Low tumor interleukin-1β expression predicts a limited effect of adjuvant platinum-based chemotherapy for patients with completely resected lung adenocarcinoma: An identification and validation study.
%J Pulmonology
%V nn
%@ 2531-0429
%C Amsterdam
%I Elsevier
%M DKFZ-2024-00784
%P nn
%D 2024
%X Adjuvant platinum-based chemotherapy for completely resected non-small cell lung cancer is associated with modest improvement in survival; nevertheless, no validated biomarker exists for predicting the benefit or harm of adjuvant platinum-based chemotherapy.We simultaneously measured 27 cytokines in operative tumor specimens from a discovery cohort (n = 97) by multiplex immunoassay; half of the patients received adjuvant platinum-based chemotherapy, and the other half were observed. We tested possible prognostic and predictive factors in multivariate Cox models for overall survival (OS) and relapse-free survival (RFS), and a tree-based method was applied to detect predictive factors with respect to RFS. The results were validated in an independent validation cohort (n = 93).Fifty-two of 97 (54 
%K Biomarkers (Other)
%K Cytokines (Other)
%K IL-1β (Other)
%K Lung neoplasms (Other)
%K Tumor microenvironment (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:38614857
%R 10.1016/j.pulmoe.2024.03.003
%U https://inrepo02.dkfz.de/record/289462